Edison Pharma and Dainippon Sumitomo Pharma (DSP) enter $4 billion metablosim drug deal
31 January 2014 | By Edison Pharmaceuticals
Novel partnership in drugs targeting biological energy...
List view / Grid view
News
Abbvie completes largest phase iii program of an all-oral, interferon-free therapy for the treatment of hepatitis c genotype 1
31 January 2014 | By AbbVie
AbbVie announced the completion of its phase III clinical program and released results of four additional studies designed to assess AbbVie's investigational all-oral, interferon-free therapy...
Roche delivers strong 2013 results
30 January 2014 | By Roche
Roche’s CEO Severin Schwan: “2013 was a very good year for Roche. We exceeded our financial targets with strong demand for our existing products and positive uptake of recently launched medicines and diagnostics...
Biogen Idec and UCB enter agreements to commercialize multiple sclerosis and hemophilia therapies in Asia
30 January 2014 | By Biogen Idec
Relationship leverages UCB’s expertise and presence in Asia to bring Biogen Idec’s Innovative therapies to patients in new markets...
Amgen announces positive top-line results from Phase 3 RUTHERFORD-2 trial of evolocumab in patients with heterozygous familial hypercholesterolemia
30 January 2014 | By Amgen
RUTHERFORD-2 study meets co-primary endpoints of ldl cholesterol reduction Amgen also announces results from phase 3 study with automated mini-doser completion of fifth phase 3 study forms basis for global filing plan...
Teva announces U.S. FDA approval of three-times-a-week COPAXONE® 40mg/mL
28 January 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that the FDA has approved the Company’s supplemental new drug application for three-times-a-week COPAXONE® 40mg/mL...
Merck statement on FDA Advisory Committee meeting for RAGWITEK™, an investigational sublingual allergy immunotherapy tablet
28 January 2014 | By Merck
Merck said it was pleased with the positive discussion of RAGWITEK™ at the Allergenic Products Advisory Committee meeting of the U.S. Food and Drug Administration...
Tecan offers Cavro® air displacement pipettor option for Cavro Omni Robot
28 January 2014 | By kdm communications limited
Tecan has introduced a Cavro® ADP (Air Displacement Pipettor) module for the popular Cavro Omni Robot...
Amgen announces positive top-line results from Phase 3 LAPLACE-2 trial of Evolocumab (AMG 145) in combination with statins in patients with high cholesterol
28 January 2014 | By Amgen
Amgen announced that the Phase 3 LAPLACE-2 trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints...
Live cellular FRET fluorescent protein assay (mTFP-YFP) – No filters needed
28 January 2014 | By BMG LABTECH
When adapting a fluorescent protein assay from a confocal microscope to a microplate format, researchers no longer need filters thanks to new LVF Monochromators™ in the CLARIOstar® microplate reader from BMG LABTECH...
Sanofi celebrates 50th anniversary of France – China relations
27 January 2014 | By Sanofi
Sanofi announced its participation in the commemoration of the 50th anniversary of diplomatic relations between France and the People's Republic of China...
Pfizer announces top-line results from two Phase 3 trials of Dacomitinib on patients with refractory advanced non-small cell lung cancer
27 January 2014 | By Pfizer
An Ongoing, Third Phase 3 Trial is Evaluating Dacomitinib in First-Line in EGFR-Mutant NSCLC...
Novartis recognized among world’s most sustainable companies in Corporate Knights Global 100
27 January 2014 | By Novartis
Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100...
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU
24 January 2014 | By Novartis
Novartis announced it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure...
Novartis reports positive opinion from CHMP for Xolair® in severe form of skin disease CSU, a debilitating form of hives and chronic itch
Novartis announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the use of Xolair®...
